Symphogen sold to Servier

The French international pharmaceutical company Servier has entered into an agreement to buy the biotech company Symphogen. Plesner has advised the sellers of Symphogen in relation to the transaction.

Symphogen is a Danish biotech company with a leading position in therapeutic antibody discovery. The transaction will strengthen Servier’s antibody capabilities and ensure that Symphogen’s antibody discovery and early-development platform is fully utilized.

Through the acquisition Servier will gain full ownership of Symphogen, including the proprietary pipeline of oncology and immuno-oncology programs and Symphogen's antibody discovery and development platform. Symphogen will maintan its activities in Ballerup (Denmark) and will continue as Servier's antibody center of excellence for its therapeutic areas.

Servier has its headquarters in France and is governed by a foundation. With presence in 149 countries the company employs 22,000 people worldwide. In 2019 Servier had a total revenue of EUR 4.6 billion.

Latest news on M&A and Capital Markets

Capital Markets